A5020980740- Advanced Radiotherapy Techniques
- Prostate Cancer Treatment and Research
- Prostate Cancer Diagnosis and Treatment
- Brain Metastases and Treatment
- Glioma Diagnosis and Treatment
- Radiopharmaceutical Chemistry and Applications
- Health Systems, Economic Evaluations, Quality of Life
- Lung Cancer Diagnosis and Treatment
- Advances in Oncology and Radiotherapy
- Meningioma and schwannoma management
- Cancer, Lipids, and Metabolism
- Bladder and Urothelial Cancer Treatments
- Radiation Dose and Imaging
- Esophageal Cancer Research and Treatment
- COVID-19 and healthcare impacts
- Telemedicine and Telehealth Implementation
- Lung Cancer Treatments and Mutations
- Nursing education and management
- Advanced Neural Network Applications
- Urologic and reproductive health conditions
- Radiation Therapy and Dosimetry
- Medical Image Segmentation Techniques
- PARP inhibition in cancer therapy
- Cholesterol and Lipid Metabolism
- Electronic Health Records Systems
University of California, Los Angeles
2018-2022
Toledo Clinic Cancer Center
2021-2022
Baylor College of Medicine
1985-2020
UCLA Medical Center
2019
The University of Texas MD Anderson Cancer Center
2011-2015
aTyr Pharma (United States)
2010
University of Pittsburgh
2007
Emerging data suggest that metastasis is a spectrum of disease burden rather than binary state, and local therapies, such as radiation, might improve outcomes in oligometastasis. However, current definitions oligometastasis are solely numerical. To characterize the somatic mutational landscape across metastatic castration-sensitive prostate cancer (mCSPC) to elucidate biological definition oligometastatic CSPC. This was retrospective study men with mCSPC who underwent clinical-grade...
This March 2009 Workshop Summary Report was sponsored by Product Quality Research Institute (PQRI) based on a proposal the Inhalation and Nasal Technology Focus Group (INTFG) of American Association Pharmaceutical Scientists (AAPS). Participants from pharmaceutical industry, academia regulatory bodies United States, Europe, India, Brazil attended workshop with objective presenting, reviewing, discussing recommendations for demonstrating bioequivalence (BE) that may be considered in...
<b>Rationale:</b> Standardized staging and quantitative reporting is necessary to demonstrate the association of <sup>18</sup>F-DCFPyL PET/CT (PSMA) imaging with clinical outcome. This work introduces an automated platform implement extend Prostate Cancer Molecular Imaging Evaluation (PROMISE) criteria - aPROMISE. The objective validate performance aPROMISE in quantifying disease burden patients prostate cancer who undergo PSMA Imaging. <b>Methods:</b> was a retrospective analysis 109...
PURPOSE: Magnetic resonance–guided radiation therapy (MRgRT) has recently become commercially available, offering the opportunity to accurately image and target moving tumors as compared with computed tomography-guided (CTgRT) systems. However, costs of delivering care these 2 modalities remain poorly described. With localized unresectable hepatocellular carcinoma an example, we were able use time-driven activity-based costing determine cost treatment on linear accelerators CTgRT MRgRT....
Object Brain metastases present a therapeutic challenge because patients with metastatic cancers live longer now than in the recent past due to systemic therapies that, while effective, may not penetrate blood-brain barrier. In study authors sought validate Diagnosis-Specific Graded Prognostic Assessment (DS-GPA), new prognostic index that takes into account histological characteristics of primary tumor, and Radiation Therapy Ontology Group Recursive Partitioning Analysis (RPA) system by...
The treatment paradigm for metastatic hormone-sensitive prostate cancer (mHSPC) patients is evolving. PET/CT now offers improved sensitivity and accuracy in staging. Recent randomized trial data supports escalated hormone therapy, local primary tumor metastasis-directed therapy. impact of combining such therapies into a multimodal approach unknown. This Phase II single-arm clinical sponsored funded by Veterans Affairs combines local, metastasis-directed, systemic to durably render free...
Stereotactic body radiation therapy (SBRT) has become a standard-of-care option for localized prostate cancer. While SBRT traditionally been delivered using computed-tomography-guided (CTgRT), MR-imaging-guided (MRgRT) is now available. MRgRT offers real-time soft-tissue visualization and ease of adaptive planning, obviating the need fiducial markers, potentially allowing smaller planning target volume (PTV) margins. Although prior studies have focused on evaluating cost-effectiveness vs...
Monoclonal antibodies (IgM kappa) have been produced to actin isolated electrophoretically from L cell extracts. These monoclonal anti-actin bind intact cells and modulate DNA synthesis proliferation, much like affinity-purified polyclonal rabbit antibody the same Mr 42,000 actin. In addition, specific for Entamoeba histolytica also bound modulated growth of cells. A directed against a neuroblastoma surface antigen did not produce stimulation cells, binding activity was removed by absorption...
Our purpose was to study the effect of 2-(3-{1-carboxy-5-[(6-[18F]fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid (18F-DCFPyL) positron emission tomography (PET)-computed (CT) on staging/treatment recommendations previously untreated prostate cancer. We report here results a prospective single center arm imaging trial within Veterans Affairs (Greater Los Angeles): frequency patients upstaged M1 disease (primary endpoint) and with change in treatment (secondary endpoint)....
Purpose Clinical sites utilizing magnetic resonance imaging (MRI)‐only simulation for prostate radiotherapy planning typically use fiducial markers pretreatment patient positioning and alignment. Fiducial appear as small signal voids in MRI images are often difficult to discern. Existing clinical methods marker localization require multiple sequences and/or manual interaction specialized expertise. In this study, we develop a robust method automatic detection quantify the alignment accuracy...
Patients with prostate cancer treated stereotactic body radiation therapy (SBRT) may experience gastrointestinal (GI) toxicity. The hydrogel mitigate this toxicity by reducing the rectal dose. purpose of study is to compare dose and GI in patients receiving SBRT without hydrogel.Consecutive between February 2017 January 2020 were retrospectively identified. Baseline characteristics including volume, diameter, mass index (BMI), age, pretreatment prostate-specific antigen (PSA), Gleason score,...
Given its minimally invasive nature and effectiveness, stereotactic radiosurgery (SRS) has become a mainstay for the multimodal treatment of intracranial neoplasm. However, no studies have evaluated recent trends in use SRS versus those open resection management brain tumor or involvement neurosurgeons (which is primarily delivered by radiation oncologists). Here, authors used publicly available Medicare data from 2009 to 2018 elucidate neoplasm compare reimbursements between these...
147 Background: Androgen deprivation therapy (ADT) has historically been used as the backbone of treatment in patients with newly-diagnosed hormone-sensitive metastatic prostate cancer. However, recent literature suggested potential utility metastasis-directed (MDT) a subset oligometastatic cancer (OPC), potentially allowing for ADT-free survival. Methods: A cost-effectiveness analysis was performed comparing (1) ADT upfront versus (2) MDT followed by salvage asymptomatic OPC. delivered via...